Free Trial

TransMedics Group (TMDX) Competitors

TransMedics Group logo
$117.38 +2.20 (+1.91%)
Closing price 04:00 PM Eastern
Extended Trading
$118.60 +1.22 (+1.04%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TMDX vs. SNN, SOLV, PEN, STVN, GKOS, BLCO, IRTC, SLNO, NVST, and LIVN

Should you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), iRhythm Technologies (IRTC), Soleno Therapeutics (SLNO), Envista (NVST), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

TransMedics Group vs. Its Competitors

Smith & Nephew SNATS (NYSE:SNN) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by insiders. Comparatively, 7.0% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

TransMedics Group has a net margin of 13.49% compared to Smith & Nephew SNATS's net margin of 0.00%. TransMedics Group's return on equity of 28.02% beat Smith & Nephew SNATS's return on equity.

Company Net Margins Return on Equity Return on Assets
Smith & Nephew SNATSN/A N/A N/A
TransMedics Group 13.49%28.02%8.64%

Smith & Nephew SNATS has higher revenue and earnings than TransMedics Group. Smith & Nephew SNATS is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew SNATS$5.81B2.81$412M$2.1617.26
TransMedics Group$441.54M9.06$35.46M$1.9360.82

In the previous week, TransMedics Group had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 15 mentions for TransMedics Group and 11 mentions for Smith & Nephew SNATS. TransMedics Group's average media sentiment score of 1.34 beat Smith & Nephew SNATS's score of 1.03 indicating that TransMedics Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Smith & Nephew SNATS
5 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
TransMedics Group
9 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Smith & Nephew SNATS has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500.

Smith & Nephew SNATS presently has a consensus target price of $36.00, indicating a potential downside of 3.43%. TransMedics Group has a consensus target price of $123.00, indicating a potential upside of 4.79%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than Smith & Nephew SNATS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew SNATS
0 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
TransMedics Group
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.78

Summary

TransMedics Group beats Smith & Nephew SNATS on 14 of the 17 factors compared between the two stocks.

Get TransMedics Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TMDX vs. The Competition

MetricTransMedics GroupMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$4.00B$6.86B$5.74B$9.78B
Dividend YieldN/A1.29%4.40%4.04%
P/E Ratio60.8226.4431.5526.39
Price / Sales9.0665.75382.8986.63
Price / Cash69.8721.5337.7259.11
Price / Book12.586.8510.106.62
Net Income$35.46M$176.42M$3.26B$265.42M
7 Day Performance-3.69%3.36%3.58%3.45%
1 Month Performance8.56%-2.07%3.69%0.45%
1 Year Performance-33.35%8.13%37.69%19.41%

TransMedics Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TMDX
TransMedics Group
2.8893 of 5 stars
$117.38
+1.9%
$123.00
+4.8%
-32.3%$4.00B$441.54M60.82210Positive News
Analyst Forecast
SNN
Smith & Nephew SNATS
2.9734 of 5 stars
$36.45
+0.7%
$36.00
-1.2%
+21.4%$15.97B$5.81B16.8817,349Positive News
SOLV
Solventum
1.4851 of 5 stars
$71.39
0.0%
$85.75
+20.1%
+21.1%$12.40B$8.25B33.1022,000Positive News
Analyst Downgrade
PEN
Penumbra
4.7531 of 5 stars
$253.68
+0.3%
$300.47
+18.4%
+31.6%$9.89B$1.28B67.474,500
STVN
Stevanato Group
N/A€22.57
-0.2%
N/A+9.5%€6.84B€1.19B41.805,521Positive News
GKOS
Glaukos
4.7258 of 5 stars
$90.80
+1.0%
$127.42
+40.3%
-29.6%$5.21B$432.95M-55.03780News Coverage
Analyst Revision
BLCO
Bausch + Lomb
1.5692 of 5 stars
$14.56
+0.0%
$15.56
+6.9%
-9.8%$5.16B$4.79B-18.6713,500
IRTC
iRhythm Technologies
1.2918 of 5 stars
$156.40
-2.6%
$157.30
+0.6%
+140.7%$5.03B$591.84M-53.452,000
SLNO
Soleno Therapeutics
4.5659 of 5 stars
$70.56
-1.5%
$114.30
+62.0%
+50.9%$3.75BN/A-17.0630News Coverage
Analyst Forecast
NVST
Envista
3.6925 of 5 stars
$20.65
+0.1%
$20.92
+1.3%
+14.8%$3.44B$2.51B64.6712,300
LIVN
LivaNova
1.6159 of 5 stars
$53.42
-0.6%
$59.29
+11.0%
+21.4%$2.92B$1.25B-13.732,900Positive News

Related Companies and Tools


This page (NASDAQ:TMDX) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners